Last reviewed · How we verify
NCT06648473
Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib
NA trial testing MRI Scan in Low Grade Glioma of Brain. Withdrawn.
1 December 2027
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Start date | 1 January 2026 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MRI Scan
Conditions studied
- Low Grade Glioma of Brain — all drugs for Low Grade Glioma of Brain →
Sponsor
Duke University
Who can join
Adults 18 to 70, any sex, with Low Grade Glioma of Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the repeatability of magnetic resonance imaging (MRI) in patients with isocitrate dehydrogenase 1 (IDH1) mutant (mIDH1) low-grade diffuse glioma \[World Health Organization (WHO) grade 2\] who are receiving off-label ivosidenib.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06648473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MRI Scan
Trials testing the same drug.
- NCT07415018 — Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease · NA · not yet recruiting
- NCT07472491 — A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients · Phase 2, PHASE3 · recruiting
- NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
- NCT06199479 — Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancie · Phase 1 · recruiting
- NCT05121896 — Functional MRI Study Facial Synkinesis · NA · completed
Other recruiting trials for Low Grade Glioma of Brain
Currently open trials in the same condition.
- NCT07506239 — Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma · NA · recruiting
- NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
- NCT04859725 — HyperSpectral Imaging in Low Grade Glioma · NA · recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06648473 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 28 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06648473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing